Log in to post a reply
Oct 16, 2018 04:08PM
Mudpie for Opdivo trials you need to search for nivolumab. I found 31 breast cancer trials currently recruiting.
There are some passive immunotherapy drugs approved for breast cancer. Herceptin, Perjeta, and Kadcyla (TDM-1) are considered passive immunotherapies, as is Opdivo. Those are the only three currently approved that I am aware of unless something else has very recently been approved. Unfortunately only about 20% of us are HER2+ and can take advantage of them (and I give thanks every day that I'm in the 20%). Your profile isn't visible (or hasn't been added) so I don't know your HER2 status or what treatments you've previously had.
I don't think that Keytruda, a check point inhibitor immunotherapy, has been approved for breast cancer yet, but it seems close and promising for TNBC.
There's nothing approved yet (AFAIK) for people who are not HER2+, nothing approved yet in the way of active immunotherapy, no CAR T cell therapies approved for solid tumors yet, no approved checkpoint inhibitors. It's all still in research. A quick check of clinical trials found 93 active trials for breast cancer immunotherapy (66 currently recruiting) so it might be worth a look at more than just nivolumab.
IBC Stage IV de novo - mets throughout skeleton (bones & now bone marrow), liver, dozens of distant nodes, chest wall/pec muscle, skin, tumor in brachial nerves, thyroid, polycythemia from bone marrow involvement
9/8/2017, IBC, Right, Stage IV, metastasized to bone/liver/other, Grade 3, ER+/PR-, HER2+ (IHC)
9/26/2017 Taxol (paclitaxel)
2/6/2018 Perjeta (pertuzumab)
2/6/2018 Herceptin (trastuzumab)
11/26/2018 Taxol (paclitaxel)
1/30/2019 Whole-breast: Breast, Lymph nodes, Chest wall
Kadcyla (T-DM1, ado-trastuzumab)